Ticagrelor and clopidogrel showed similar ischemic stroke and hemorrhage risks after flow diversion, but ticagrelor had a significantly higher all-cause mortality risk.
Does ticagrelor improve ischemic stroke, hemorrhage, or mortality outcomes compared to clopidogrel in patients undergoing endovascular flow diversion for unruptured intracranial aneurysms?
In real-world practice for patients undergoing endovascular flow diversion, ticagrelor offers no ischemic or hemorrhagic benefit over clopidogrel but is associated with higher all-cause mortality.
Absolute Event Rate: 0% vs 0%
In real-world practice, ticagrelor and clopidogrel for patients undergoing FD were equivalent in terms of ischemic stroke and hemorrhage risks, though ticagrelor was associated with a significantly higher risk of all-cause mortality.
Chen et al. (Mon,) reported a other. Ticagrelor and clopidogrel showed similar ischemic stroke and hemorrhage risks after flow diversion, but ticagrelor had a significantly higher all-cause mortality risk.